Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Mylotarg (gemtuzumab ozogamicin) injection is used for treating adults and pediatric patients who are 1 month old and older with newly diagnosed acute myeloid leukemia (AML). It is also used for treating adults and pediatric patients who are 2 years of age and older with relapsed or refractory AML.
Fact Table | |
---|---|
Formula | C6518H9916N1734O2065S40 |
License | FDA approved |
Bioavailability | Not applicable (intravenous administration) |
Legal status | Prescription only |
Chemical Name | Gemtuzumab Ozogamicin |
Elimination half-life | Approximately 62 hours |
Dosage (Strength) | 4.5 mg/vial |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Mylotarg |
Protein binding | Not significantly bound |
PubChem CID | 24972295 |
MedlinePlus | a607044 |
ChEBI | 134722 |
ATC code | L01XC05 |
DrugBank | DB00056 |
KEGG | D04252 |
Routes of administration | Intravenous |
Your treatment plan will be prescribed by your healthcare provider. A healthcare professional will administer Mylotarg intravenous (IV) infusion. Any questions or concerns may be referred to your healthcare provider.
Gemtuzumab ozogamicin is the active ingredient in Mylotarg.
Dextran 40 (41.0 mg), sodium chloride (26.1 mg), sodium phosphate dibasic anhydrous (2.7 mg), sodium phosphate monobasic monohydrate (0.45 mg), and sucrose (69.8 mg). After reconstitution with 5 mL of Sterile Water for Injection USP, the concentration is 1 mg/mL of gemtuzumab ozogamicin with a deliverable volume of 4.5 mL (4.5 mg) are the inactive ingredients.
Mylotarg should not be administered to patients with an allergy to any of its ingredients.
Mylotarg side effects include but are not limited to bleeding, infection, fever, nausea, vomiting, constipation, headache, increased liver enzymes, rash, inflamed mouth or gut, low neutrophil counts with a fever, and decreased appetite. Let your healthcare provider know right away if you experience bothersome or persistent side effects.
Talk to your healthcare provider about Mylotarg.
Mylotarg. Philadelphia, PA: Wyeth Pharmaceuticals LLC; 2021.